Vignette 1 of 1· source #1
AF patient asks about fish oil
Objective · Avoidance of AF-aggravating doses.
A 70-year-old with paroxysmal AF on flecainide asks about 4 g/d EPA+DHA for 'general heart health.'
Best advice?
Curriculum
Module 08 · 60 min
Omega-3 Fatty Acids — EPA, DHA & the AF Signal
From REDUCE-IT to STRENGTH and OMEMI — what high-dose omega-3 actually does.
CoreClinicalAdvanced
Core topics
Lessons in this module
Learning objectives
By the end of this module you will be able to
- L01Distinguish icosapent ethyl (Vascepa) from OTC fish oil mechanistically and by RCT outcomes.
- L02Counsel a patient on AF risk with high-dose (≥4 g/d) EPA+DHA.
- L03Identify defensible indications: hypertriglyceridemia adjunct, secondary prevention per REDUCE-IT, pregnancy DHA.
- L04Critique REDUCE-IT's mineral oil placebo.
Expected takeaways
What you should walk away believing
- →Icosapent ethyl 2 g BID reduced MACE 25% in REDUCE-IT — but mineral oil placebo confounds.
- →Mixed EPA+DHA at 4 g/d (STRENGTH, OMEMI) shows no MACE benefit and increased AF.
- →OTC fish oil quality varies widely; oxidation common.
- →EPA 1–2 g/d has modest antidepressant evidence as add-on therapy.
Lesson · Core emphasis
What this means for you
Patient summary
There's one prescription fish-oil derivative (icosapent ethyl) that lowered heart-attack risk in a big trial, but other studies of regular fish oil pills didn't help and some increased an irregular heart rhythm. Talk to your doctor before adding high-dose fish oil.
Clinician summary
Reserve icosapent ethyl 2 g BID for REDUCE-IT-eligible secondary prevention. Do not equate to OTC fish oil. Counsel pregnant patients on 200–300 mg DHA from low-mercury fish or supplement. Caution AF history with high-dose omega-3.
Advanced note
The mineral oil placebo in REDUCE-IT raised LDL and hsCRP, possibly inflating the effect size — STRENGTH used corn oil and was null. Ongoing debate; AHA still recommends icosapent ethyl per current guidelines.
Evidence framework
Where this module sits on the device evidence map
Omega-3: prescription vs OTC distinction is the central counseling teaching.
Myth-buster
More fish oil is always better for the heart.
Reality
≥4 g/d EPA+DHA increased AF risk in OMEMI and STRENGTH.
Evidence-graded claims
What the data says
A
Icosapent ethyl 4 g/d reduces MACE in secondary prevention
REDUCE-IT (caveat: mineral oil placebo).
F
OTC fish oil prevents primary CV events in well-treated patients
VITAL, ASCEND, OMEMI.
B
EPA ≥1 g/d as adjunct in unipolar depression provides modest benefit
Meta-analyses positive but heterogeneous.
Objective self-check
Test the learning objectives
Score0 / 1(0 answered)
Q1L01 — High-dose mixed EPA+DHA signal?
Case vignettes
Apply it: real-world counseling scenarios
Short patient encounters that test your judgment, not your recall. Pick the most defensible response, then reveal the rationale and a sample coaching script you could actually say at the bedside.
Vignette proficiency
In progress · 0/1 submitted
Correct0/1 (0%)Pitfalls avoided0/0 (0%)Composite0
Composite weighting
Accuracy 60%Pitfalls 40%
← all pitfallsbalancedall accuracy →
Composite = 60% answer accuracy + 40% pitfalls avoided. Your weighting is saved for this module.
Order · randomized[1]
Quick check
Test yourself
Q1REDUCE-IT primary endpoint reduction?
Q2OMEMI signal?
Flashcards · Spaced repetition
Lock it in — review what's due
Due2Total2
FrontNew
2 in queueREDUCE-IT product?
Click to reveal answer
Glossary
Key terms & abbreviations
- Icosapent ethyl
- Prescription ethyl ester of EPA; FDA-approved 2019 for CV risk reduction.
- MACE
- Major adverse cardiovascular event — composite of CV death, MI, stroke, revascularization.
Further reading
Optional deeper dive
- REDUCE-IT — Bhatt et al. — NEJM 2019↗
- STRENGTH — Nicholls et al. — JAMA 2020↗